CD274 and Hyperglycemia: It was reported that hyperglycemia is a rare adverse event of sintilimab in phase 2 clinical trial (1%, or 1 of 96 subjects).[4] The prevalence is similar to those who received other PD-1 or PD-L1 inhibitor therapy (∼1%).[7] Despite this adverse event's low incidence, it can be associated with a potentially life-threatening condition, diabetic ketoacidosis, if not be recognized and adequately treated soon enough.